Kesavan, Murali <br/><br/>
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.  [electronic resource] 

 -  Neuroendocrinology  2014 
 - 108-17 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1423-0194 
<br/><br/><label>Standard No.: </label>10.1159/000362558  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anemia--chemically induced<br/>Antineoplastic Agents--adverse effects<br/>Blood Platelets--drug effects<br/>Capecitabine<br/>Dacarbazine--adverse effects<br/>Deoxycytidine--adverse effects<br/>Digestive System Neoplasms--drug therapy<br/>Drug Therapy, Combination<br/>Female<br/>Fluorouracil--adverse effects<br/>Follow-Up Studies<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Incidence<br/>Intestinal Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Neuroendocrine Tumors--drug therapy<br/>Neutrophils--drug effects<br/>Octreotide--adverse effects<br/>Pancreatic Neoplasms--drug therapy<br/>Radiopharmaceuticals--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Stomach Neoplasms--drug therapy<br/>Temozolomide<br/>Thrombocytopenia--chemically induced<br/>Treatment Outcome